<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 03, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321278</url>
  </required_header>
  <id_info>
    <org_study_id>30155020.5.1001.0071</org_study_id>
    <nct_id>NCT04321278</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</brief_title>
  <official_title>Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brazilian Research In Intensive Care Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
      infectious disease of the respiratory tract. Around 20% of those infected have severe
      pneumonia and currently there is no specific or effective therapy to treat this disease.
      Therapeutic options using malaria drugs chloroquine and hydroxychloroquine have shown
      promising results in vitro and in vivo test. But those efforts have not involved large,
      carefully-conducted controlled studies that would provide the global medical community the
      proof that these drugs work on a significant scale. In this way, the present study will
      evaluate the effectiveness and safety of the use of hydroxychloroquine combined with
      azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with
      pneumonia by SARS-CoV2 virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized
      infectious disease of the respiratory tract that is now spreading to several countries in the
      world, including Brazil. Mortality rates after infection are higher in adults over 60 and
      with a history of comorbidities. The most serious patients need care in intensive care units
      (ICU). Most of the time they depend on mechanical ventilation support due to acute
      respiratory distress syndrome (ARDS). Infection rates are higher than the capacity for
      intensive care, which represents a serious problem in medical care. Around 20% of those
      infected have severe pneumonia and so far it does not have a specific therapy, or even, an
      effective clinical management. Therapeutic options using malaria drugs chloroquine and
      hydroxychloroquine have shown promising results in vitro and in vivo test. A recent, small,
      non-randomized study with hydroxychloroquine in 36 patients infected with SARS-Cov-2 proved
      to be promising in the ability to reset the viral load in 6 days after starting treatment.
      Thus, the present study will evaluate the effectiveness and safety of the use of
      hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in
      the clinical evolution by the ordinal scale of 7 points in adult patients hospitalized with
      pneumonia caused by infection by the SARS-CoV2 virus in Brazil.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the clinical status</measure>
    <time_frame>15 days after randomization</time_frame>
    <description>Evaluation of the clinical status of patients on the 15th day after randomization defined by the Ordinal Scale of 7 points (score ranges from 1 to 7, with 7 being the worst score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>29 days after randomization</time_frame>
    <description>All-cause mortality rates at 29 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days free from mechanical ventilation</measure>
    <time_frame>29 days after randomization</time_frame>
    <description>Number of days free from mechanical ventilation at 29 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>7, 15 and 29 days after randomization</time_frame>
    <description>Number of days that the patient was on mechanical ventilation after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>7, 15 and 29 days after randomization</time_frame>
    <description>Length of hospital stay on survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary infections</measure>
    <time_frame>7, 15 and 29 days after randomization</time_frame>
    <description>Presence of other secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from treatment start to death</measure>
    <time_frame>7, 15 and 29 days after randomization</time_frame>
    <description>Time from treatment start to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Coronavirus Infections</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine [400mg 2x/day, 12/12h]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine + azithromycin</intervention_name>
    <description>Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.</description>
    <arm_group_label>Hydroxychloroquine + azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged &gt; 18 years;

          2. Probable or confirmed infection by SARS-CoV2 presenting with one of the following:

               -  Need for oxygen supplementation &gt; 4L or,

               -  Need for high oxygen flow nasal catheter, or

               -  Need for non-invasive ventilation, or

               -  Need for mechanical ventilation.

        Exclusion Criteria:

          1. Refusal to provide written informed consent (either the patient or a legal
             representative);

          2. Hypersensitivity to any of the drugs used in the study (Azithromycin or
             Hydroxychloroquine);

          3. Patients with long QT syndrome or severe ventricular arrhythmias;

          4. QTc&gt; = 480ms;

          5. Patients without a therapeutic perspective or with a palliative care perspective;

          6. Patients with liver disease or cirrhosis or abnormal liver enzyme tests above three
             times the upper limit values (alanine aminotransferase -ALT and aspartate
             aminotransferase - AST);

          7. Renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73m2,
             using the MDRD or CKD-EPI methods);

          8. Patients with retinopathy or macular degeneration;

          9. Patients with pancreatitis;

         10. Patients using drugs that prolong the QT interval;

         11. Patients with concomitant use of medications that alter the absorption or excretion of
             azithromycin or hydroxychloroquine;

         12. Breastfeeding women;

         13. Patients using psychoactive drugs;

         14. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otávio Berwanger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ARO-HIAE Academic Research Organization HIAE</last_name>
    <phone>+55 (11) 2151-1233</phone>
    <email>aro.clinicaltrials@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrique Fonseca, PhD</last_name>
    <phone>+55 (11) 2151-1233</phone>
    <email>henrique.fonseca@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo S Biondi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rodrigo S Biondi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Social Rural de Colatina</name>
      <address>
        <city>Colatina</city>
        <state>Espirito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo C Figueiredo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rodrigo C Figueiredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz AS</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando C Neuenschwander, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fernando C Neuenschwander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Maternidade E Pronto Socorro Santa Lucia Ltda</name>
      <address>
        <city>Poços De Caldas</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederico TC DallOrto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frederico TC DallOrto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cintia MC Grion, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cintia MC Grion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Onofre Lopes</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria SM Paiva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria SM Paiva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thiago C Lisboa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thiago C Lisboa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maestri E Kormann Consultoria Medico-Cientifica</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian PM Kormann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrian PM Kormann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sociedade Literaria e Caritativa Santo Agostinho</name>
      <address>
        <city>Criciúma</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Dal Pizzol, MD</last_name>
    </contact>
    <investigator>
      <last_name>Felipe Dal Pizzol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina P Amendola, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina P Amendola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro E Hernandes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro E Hernandes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otávio Berwanger, PhD</last_name>
      <phone>+55 (11) 2151-1233</phone>
      <email>aro.clinicaltrials@einstein.br</email>
    </contact>
    <contact_backup>
      <last_name>Henrique Fonseca, PhD</last_name>
      <phone>+ 55 (11) 2151-1233</phone>
      <email>henrique.fonseca@einstein.br</email>
    </contact_backup>
    <investigator>
      <last_name>Ótávio Berwanger, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrique Fonseca, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remo Furtado, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ary Serpa-Neto, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thiago Correa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cláudio Galvão, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonardo R Ferraz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilherme Schettino, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz V Rizzo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMICO Saude LTDA</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio H Lacerda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio H Lacerda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associacao Beneficente Siria</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando G Zampieri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fernado G Zampieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prevent Senior Private Operadora de Saude Ltda</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla MG Godoy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carla MG Godoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência/SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane C Veiga, MD</last_name>
    </contact>
    <investigator>
      <last_name>Viviane C Veiga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência/SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre M Soeiro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre M Soeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge LR Paranhos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge LR Paranhos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Secretaria de Saúde do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israel S Maia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Israel S Maia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Serv Social da Industria do papel, papelão e cortiça do estado de SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flavio GR Freitas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Flavio GR Freitas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano CP Azevedo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luciano CP Azevedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia R Machado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Flavia R Machado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV2 virus</keyword>
  <keyword>2019-nCOV</keyword>
  <keyword>COVID-19</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

